Form 4: Amylyx Pharmaceuticals' Chief Legal Officer Receives Stock and Option Awards

Gina Mazzariello, Chief Legal Officer of Amylyx Pharmaceuticals, receives restricted stock units and stock options.

Summary

• Gina Mazzariello, Chief Legal Officer of Amylyx Pharmaceuticals, received 36,667 restricted stock units (RSUs) and options to purchase 55,000 shares of common stock on February 26, 2024.
• The RSUs vest in four equal annual installments, starting one year from the grant date, contingent upon continued service.
• The stock options vest over 48 months, with 1/4 vesting after one year and the remainder vesting monthly over the following 36 months, also contingent upon continued service.
• The exercise price of the stock options is $17.56.
• Following the transaction, Mazzariello directly owns 82,912 shares of common stock and options for 55,000 shares.

Sentiment

Score: 7

Explanation: The document reflects a standard executive compensation practice, which is generally viewed neutrally to positively as it aligns management interests with shareholders.

Positives

• The grant of RSUs and stock options aligns the Chief Legal Officer's interests with those of the shareholders, incentivizing her to contribute to the company's long-term success.
• The vesting schedules for both the RSUs and stock options encourage continued service and commitment to Amylyx Pharmaceuticals.

Future Outlook

The document does not contain any specific forward-looking statements regarding the company's future performance.

Industry Context

Equity compensation is a common practice in the pharmaceutical industry to attract and retain key personnel. The size and terms of the grants are generally aligned with industry standards for similar roles and company size.

Comparison to Industry Standards

• Equity compensation packages for Chief Legal Officers in publicly traded pharmaceutical companies typically include a mix of stock options and restricted stock units.
• The vesting schedules described in the document (annual and monthly vesting over several years) are standard practice to incentivize long-term commitment.
• The specific value of the grants would need to be compared to peer companies of similar size and stage of development to determine if they are within industry norms.

Stakeholder Impact

• Shareholders may view the equity grants as a positive sign, aligning management's interests with the company's long-term success.
• Employees may see the grants as a sign of the company's commitment to its leadership team.

Key Dates